Physician profile
Naveed Wagle
NPI 1871754655
$4,446.08
in general payments reported to CMS, 2019-2025
40 companies · $921 in 2025
The $921 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $285 · 2021: $77.62 · 2022: $156 · 2023: $1,700 · 2024: $774 · 2025: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,028 · Travel and Lodging: $1,068 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,028.16 |
| Travel and Lodging | $1,068.19 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $298.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,347.64 | 2023 | |
| Novocure INC. | $831.58 | 2019-2025 | Optune, Optune Gio |
| Boehringer Ingelheim International Gmbh | $298.71 | 2024 | |
| Springworks Therapeutics, INC. | $242.88 | 2025 | Gomekli |
| Gt Medical Technologies, INC | $211.10 | 2019-2025 | Gammatile |
| Merck Sharp & Dohme LLC | $143.83 | 2019-2025 | Keytruda |
| Merz Pharmaceuticals, LLC | $119.62 | 2022-2025 | Xeomin |
| E.R. Squibb & Sons, L.L.C. | $103.92 | 2020-2022 | |
| Abbvie INC. | $86.82 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $86.80 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.28 | 2020-2025 | |
| Array Biopharma INC | $68.73 | 2020-2025 | Mektovi, Braftovi, Lorbrena |
| Astrazeneca Pharmaceuticals LP | $63.33 | 2020-2024 | Enhertu |
| Baxter Healthcare | $59.86 | 2023 | Floseal |
| Neurelis, INC. | $50.82 | 2020-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Btg International INC. | $50.10 | 2025 | Voraxaze |
| Ipsen Biopharmaceuticals, INC | $48.91 | 2023-2025 | Dysport |
| Urogen Pharma, INC. | $46.53 | 2023-2025 | Jelmyto |
| Eisai INC. | $42.53 | 2019-2020 | |
| Monteris Medical Corporation | $41.95 | 2019 | |
| Jazz Pharmaceuticals INC. | $41.77 | 2025 | |
| Ge Healthcare | $40.67 | 2022-2023 | |
| Kyowa Kirin, INC. | $34.70 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $33.79 | 2024 | Ultomiris |
| Tempus Ai, INC | $31.92 | 2025 | Xt Cdx |
| Medtronic, INC. | $30.14 | 2024 | Percept PC Brainsense |
| Biohaven Pharmaceuticals, INC. | $23.69 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.47 | 2020 | |
| Lilly USA, LLC | $23.19 | 2020 | |
| Ucb, INC. | $23.08 | 2020 | |
| Blueprint Medicines Corporation | $21.84 | 2020 | |
| Genentech USA, INC. | $21.48 | 2024 | Phesgo, Perjeta |
| Microtransponder, INC. | $19.78 | 2023 | |
| Epizyme, INC. | $18.58 | 2022 | |
| Mdd US Operations, LLC | $16.32 | 2025 | |
| Daiichi Sankyo INC. | $14.72 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naveed Wagle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.